Status: Recruiting
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population
Participants needed: 40
Trial details
Age: 1-17Biological sex: AllType: ObservationalSponsor: Fresenius KabiUpdated: Sep 5, 2025Locations: 10
Eligibility criteria
Patient's parent(s) or legal guardian(s) has provided a signed and dated Informe... [+2]
Patient has received Omegaven within four weeks before inclusion in the study [+15]